Diurnal Group (DNL) Announces Quarterly Earnings Results

Diurnal Group (LON:DNL) posted its quarterly earnings data on Monday. The company reported GBX (12.70) (($0.18)) earnings per share for the quarter, Bloomberg Earnings reports.

Diurnal Group (LON DNL) traded down GBX 12.50 ($0.17) during mid-day trading on Wednesday, reaching GBX 201.50 ($2.78). The company’s stock had a trading volume of 11,715 shares, compared to its average volume of 5,226. Diurnal Group has a twelve month low of GBX 118 ($1.63) and a twelve month high of GBX 215.80 ($2.98). The stock has a market capitalization of $185.23 and a PE ratio of -1,007.50.

In other Diurnal Group news, insider John Goddard acquired 10,791 shares of the business’s stock in a transaction on Friday, January 5th. The shares were acquired at an average price of GBX 540 ($7.46) per share, with a total value of £58,271.40 ($80,507.60).

Separately, Numis Securities reissued a “buy” rating and issued a GBX 185 ($2.56) price objective on shares of Diurnal Group in a research report on Monday, December 18th.

TRADEMARK VIOLATION WARNING: “Diurnal Group (DNL) Announces Quarterly Earnings Results” was posted by Markets Daily and is the property of of Markets Daily. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.themarketsdaily.com/2018/03/14/diurnal-group-dnl-announces-quarterly-earnings-results.html.

About Diurnal Group

Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company’s products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism.

Receive News & Ratings for Diurnal Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply